Major Program
Supportive Care and Symptom Management
NCI Community Oncology Research Program
Research Group
Community Oncology and Prevention Trials
Sponsor
Children's Oncology Group
Status
Active, not recruiting
ClinicalTrials.gov ID
For more information, see ClinicalTrials.gov NCT02717507
This phase IIb trial studies how well low-dose carvedilol works in preventing heart failure
in cancer survivors exposed to high dose anthracyclines for management of childhood cancer.
Patients who received high-dose anthracycline chemotherapy are at a much greater risk for
developing heart failure compared to survivors who didn't get any anthracycline chemotherapy.
Heart failure happens when the heart muscle has been weakened and can't pump blood as well as
it should. Carvedilol may help lower the risk of cardiovascular complications.
in cancer survivors exposed to high dose anthracyclines for management of childhood cancer.
Patients who received high-dose anthracycline chemotherapy are at a much greater risk for
developing heart failure compared to survivors who didn't get any anthracycline chemotherapy.
Heart failure happens when the heart muscle has been weakened and can't pump blood as well as
it should. Carvedilol may help lower the risk of cardiovascular complications.
Intervention
Carvedilol, Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Questionnaire Administration, Pharmacogenomic Study, Placebo Administration
Condition
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Investigators
Saro H Armenian